EPS for Axovant Sciences Ltd. (AXON) Expected At $-0.39

May 17, 2018 - By Ann Prendergast

Axovant Sciences Ltd. (NASDAQ:AXON) Logo

Analysts expect Axovant Sciences Ltd. (NASDAQ:AXON) to report $-0.39 EPS on June, 12.They anticipate $0.14 EPS change or 26.42 % from last quarter’s $-0.53 EPS. The stock decreased 0.81% or $0.01 during the last trading session, reaching $1.23. About 300,896 shares traded. Axovant Sciences Ltd. (NASDAQ:AXON) has declined 90.77% since May 18, 2017 and is downtrending. It has underperformed by 102.32% the S&P500.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. The company has market cap of $132.58 million. The Company’s lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer??s disease; in Phase IIb clinical trial for treating dementia with Lewy bodies ; and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. It currently has negative earnings. The firm is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD.

Axovant Sciences Ltd. (NASDAQ:AXON) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.